These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 25917796)

  • 1. UbcH10 expression can predict prognosis and sensitivity to the antineoplastic treatment for colorectal cancer patients.
    Cacciola NA; Calabrese C; Malapelle U; Pellino G; De Stefano A; Sepe R; Sgariglia R; Quintavalle C; Federico A; Bianco A; Uchimura Bastos A; Milone M; Bellevicine C; Milone F; Carlomagno C; Selvaggi F; Troncone G; Fusco A; Pallante P
    Mol Carcinog; 2016 May; 55(5):793-807. PubMed ID: 25917796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of clinicopathological features with UbcH10 expression in colorectal cancer.
    Chen S; Chen Y; Hu C; Jing H; Cao Y; Liu X
    J Cancer Res Clin Oncol; 2010 Mar; 136(3):419-26. PubMed ID: 19779934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer.
    Geißler AL; Geißler M; Kottmann D; Lutz L; Fichter CD; Fritsch R; Weddeling B; Makowiec F; Werner M; Lassmann S
    Oncotarget; 2017 Mar; 8(10):17164-17190. PubMed ID: 28199979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. UbcH10 overexpression in human lung carcinomas and its correlation with EGFR and p53 mutational status.
    Pallante P; Malapelle U; Berlingieri MT; Bellevicine C; Sepe R; Federico A; Rocco D; Galgani M; Chiariotti L; Sanchez-Cespedes M; Fusco A; Troncone G
    Eur J Cancer; 2013 Mar; 49(5):1117-26. PubMed ID: 23102841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lauric acid can improve the sensitization of Cetuximab in KRAS/BRAF mutated colorectal cancer cells by retrievable microRNA-378 expression.
    Weng WH; Leung WH; Pang YJ; Hsu HH
    Oncol Rep; 2016 Jan; 35(1):107-16. PubMed ID: 26496897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. UbcH10 expression provides a useful tool for the prognosis and treatment of non-small cell lung cancer.
    Zhao L; Jiang L; Wang L; He J; Yu H; Sun G; Chen J; Xiu Q; Li B
    J Cancer Res Clin Oncol; 2012 Nov; 138(11):1951-61. PubMed ID: 22760214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. UbcH10 overexpression increases carcinogenesis and blocks ALLN susceptibility in colorectal cancer.
    Li SZ; Song Y; Zhang HH; Jin BX; Liu Y; Liu WB; Zhang XD; Du RL
    Sci Rep; 2014 Nov; 4():6910. PubMed ID: 25376843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combinational treatment with microRNA‑133b and cetuximab has increased inhibitory effects on the growth and invasion of colorectal cancer cells by regulating EGFR.
    Zhou J; Lv L; Lin C; Hu G; Guo Y; Wu M; Tian B; Li X
    Mol Med Rep; 2015 Oct; 12(4):5407-14. PubMed ID: 26151111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS/BRAF mutational status in colorectal cancer.
    Seo Y; Ishii Y; Ochiai H; Fukuda K; Akimoto S; Hayashida T; Okabayashi K; Tsuruta M; Hasegawa H; Kitagawa Y
    Oncol Rep; 2014 May; 31(5):2115-22. PubMed ID: 24626880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNA interference-mediated silencing of UBCH10 gene inhibits colorectal cancer cell growth in vitro and in vivo.
    Chen SM; Jiang CY; Wu JY; Liu B; Chen YJ; Hu CJ; Liu XX
    Clin Exp Pharmacol Physiol; 2010 May; 37(5-6):525-9. PubMed ID: 20529090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cetuximab in the treatment of patients with colorectal cancer.
    Garrett CR; Eng C
    Expert Opin Biol Ther; 2011 Jul; 11(7):937-49. PubMed ID: 21557708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
    Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
    J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
    Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy.
    Scartozzi M; Bearzi I; Pierantoni C; Mandolesi A; Loupakis F; Zaniboni A; Catalano V; Quadri A; Zorzi F; Berardi R; Biscotti T; Labianca R; Falcone A; Cascinu S
    J Clin Oncol; 2007 Sep; 25(25):3930-5. PubMed ID: 17761976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response.
    Signore M; Buccarelli M; Pilozzi E; De Luca G; Cappellari M; Fanciulli M; Goeman F; Melucci E; Biffoni M; Ricci-Vitiani L
    Oncotarget; 2016 Jul; 7(28):44113-44128. PubMed ID: 27286453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paxillin is positively correlated with the clinicopathological factors of colorectal cancer, and knockdown of Paxillin improves sensitivity to cetuximab in colorectal cancer cells.
    Du C; Wang X; Zhang J; Liu X; Zhu J; Liu Y
    Oncol Rep; 2016 Jan; 35(1):409-17. PubMed ID: 26530439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan.
    Kim ST; Ahn TJ; Lee E; Do IG; Lee SJ; Park SH; Park JO; Park YS; Lim HY; Kang WK; Kim SH; Lee J; Kim HC
    BMC Cancer; 2015 Oct; 15():747. PubMed ID: 26486455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L
    Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab.
    Musella V; Pietrantonio F; Di Buduo E; Iacovelli R; Martinetti A; Sottotetti E; Bossi I; Maggi C; Di Bartolomeo M; de Braud F; Daidone MG; Cappelletti V
    Int J Cancer; 2015 Sep; 137(6):1467-74. PubMed ID: 25704501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.